[{"orgOrder":0,"company":"IQVIA","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Pharmacology\/Toxicology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Noveome Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ST266","moa":"AChE","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BI690517","moa":"ALDOS","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Kintor Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyrilutamide","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dermavant Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"J147","moa":"ATP synthase (ATPS)","graph1":"Neurology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"OPS-2071","moa":"Bacterial DNA replication","graph1":"Immunology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Amoxicillin Trihydrate","moa":"Bacterial penicillin-binding protein","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase IV","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Autolus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Obecabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"ImmuneOnco","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"IMM47","moa":"CD24","graph1":"Oncology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"InflaRx","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Milestone Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Etripamil","moa":"coronary vasodilators (verapamil type)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"ProtoKinetix","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Partnership","leadProduct":"PKX-001","moa":"COX-2 expression","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ ProtoKinetix","highestDevelopmentStatusID":"4","companyTruncated":"IQVIA \/ ProtoKinetix"},{"orgOrder":0,"company":"IQVIA","sponsor":"F2G Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Olorofim","moa":"Dihydroorotate dehydrogenase (quinone), mitochondrial","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Delcath Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Talabostat Mesylate","moa":"DPP8","graph1":"Oncology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inozyme Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Inozyme Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tucidinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"HUYA Bioscience International","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tucidinostat","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Undisclosed","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Nirsevimab","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"Medicines Evaluation Unit","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Medicines Evaluation Unit","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicines Evaluation Unit \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"Medicines Evaluation Unit \/ Chiesi Group"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Otilimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Atorvastatin","moa":"HMG-CoA reductase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Argenx","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Efgartigimod","moa":"IgG receptor FcRn large subunit p51","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"ASLAN Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SINGAPORE","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"ASLAN004","moa":"IL-13-alpha-1 receptor","graph1":"Immunology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"ASLAN Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Eblasakimab","moa":"IL-13-alpha-1 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ ASLAN Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ ASLAN Pharmaceuticals"},{"orgOrder":0,"company":"IQVIA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"bacTRL-IL-12","moa":"Immune","graph1":"Oncology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ Undisclosed"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"MEDI-546","moa":"Interferon-alpha\/beta receptor alpha chain","graph1":"Immunology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"Interleukin-12 | Interleukin-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection, Pre-Filled","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Depemokimab","moa":"Interleukin-5","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Benralizumab","moa":"Interleukin-5 receptor subunit alpha","graph1":"Immunology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"TRC150094","moa":"Mitochondrial function","graph1":"Endocrinology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"||Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IQVIA \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ Undisclosed"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Olaparib","moa":"PARP 1, 2 and 3","graph1":"Oncology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Verona Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Genetic Disease","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Genetic Disease","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dimerix","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Propagermanium","moa":"quaternary ammonium derivatives","graph1":"Nephrology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Dimerix","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Propagermanium","moa":"quaternary ammonium derivatives","graph1":"Nephrology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule, Immediate Release","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ GSK"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AZD1222","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"11","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"AZD7442","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Upifitamab Rilsodotin","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Mersana Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"XMT-1592","moa":"Sodium\/phosphate cotransporter 2B (SLC34A2)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Blue Water Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Finasteride","moa":"||Steroid 5-alpha-reductase 2","graph1":"Urology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Synlogic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2019","type":"Inapplicable","leadProduct":"SYNB1891","moa":"Stimulator of interferon genes protein (TMEM173)","graph1":"Oncology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ICELAND","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AVT05","moa":"TNF-alpha receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"TAK-242","moa":"Toll-like receptor 4","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GSK1795091","moa":"Toll-like receptor 4 (TLR4)","graph1":"Oncology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter And Eliza Hall Institute Of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research"},{"orgOrder":0,"company":"IQVIA","sponsor":"Kexing Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2025","type":"Partnership","leadProduct":"Paclitaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2018","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"15","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sovleplenib","moa":"Tyrosine-protein kinase SYK","graph1":"Oncology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Tikomed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Collaboration","leadProduct":"Dextrans","moa":"TGF-beta||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Humacyte","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Acellular Tissue Engineered Vessel","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Implant","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Blueberry Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BB2603-10","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Fervent Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"FP-101","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Fervent Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FP-101","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"MinervaX","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GBS-NN\/NN2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Ixovex-1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Celyad Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"NKR-2 CAR T-Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Nocion Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NOC-110","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Organon","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OG-6219","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Two-Component COVID-19 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Spero Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tebipenem Pivoxil Hydrobromide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Arthrosi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"AR882","moa":"Urate anion exchanger 1 (URAT1)","graph1":"Nephrology","graph2":"Phase I","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"6","companyTruncated":"IQVIA \/ IQVIA"},{"orgOrder":0,"company":"IQVIA","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ IQVIA","highestDevelopmentStatusID":"4","companyTruncated":"IQVIA \/ IQVIA"}]
Find Clinical Drug Pipeline Developments & Deals by IQVIA
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
